Skip to main content
Premium Trial:

Request an Annual Quote

AccessDx Laboratory Teams With Jase Health to Embed Lab Processes Into Electronic Health Records

NEW YORK – AccessDx Laboratory said Monday that it is partnering with data integration firm Jase Health to embed lab processes into clinical workflows within major electronic health records systems.

AccessDx Lab, a Houston-based CAP/CLIA diagnostic lab, offers molecular services including COVID-19 testing, pharmacogenomic testing, cancer genomic screening, and respiratory pathogen panels. Jase Health, of Johnston, Iowa, integrates outside technologies into EHR products from Cerner, Epic Systems, Meditech, Athenahealth, Allscripts Healthcare Solutions, and others.

The firms said that the partnership will help fit personalized medication management, antibiotic stewardship, next-generation sequencing, and other lab services directly into existing clinical workflows.

"Our shared mission of efficiency has enabled our health system partners to rapidly implement and ensure advanced diagnostics solutions are seamlessly available within existing clinical decision support workflows that are positively impacting millions of patient lives," AccessDx Lab CEO Michael Stewart said in a statement. "Clinicians have seen the direct benefit of these solutions through the improved outcomes delivered by these diagnostic solutions, and we look forward to continued success in this partnership."

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.